EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial

Jessica Emily Green iD, Michael Berk iD, Mohammadreza Mohebbi, Amy Loughman, Amelia J McGuinness, David Castle iD, Mary Lou Chatterton, Joahna Perez, Philip Strandwitz, Eugene Athan, Christopher Hair, Andrew A Nierenberg und 2 weitere

The Canadian Journal of Psychiatry · 2023-05 · 68 (5) · 315-326

DOI: 10.1177/07067437221150508 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 13.01.2023. Verfasst von Jessica Emily Green und 13 weiteren Autor:innen. Beteiligte Einrichtung: Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Major Depressive Disorder. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Holobiome, Wilson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Perturbations of the intestinal microbiota have been associated with mental health disorders, including major depressive disorder (MDD). Therefore, faecal microbiota transplantation (FMT) holds promise as a microbiota-modulating treatment for MDD. Yet, to date, there are no published controlled studies evaluating the use of FMT for MDD. This study aimed to address this gap by evaluating the feasibility, acceptability, and safety of FMT for MDD.

Methods

The study was an 8-week, double-blind, 2:1 parallel group, randomized controlled pilot trial ( n = 15) of enema-delivered FMT ( n = 10) compared with a placebo enema ( n = 5) in adults with moderate-to-severe MDD.

Results

Recruitment was completed within 2 months, with 0% attrition and 100% attendance at key study appointments. There were no major protocol deviations. The placebo and blinding strategies were considered successful; nurses and participants correctly guessing their treatment allocation at a rate similar to that anticipated by chance. No serious or severe adverse events were reported in either group, and there were no significant differences in mild-to-moderate adverse events between groups (median of 2 adverse events per participant reported in both groups). Furthermore, the 12/15 participants who completed the Week 2 participant satisfaction survey agreed or strongly agreed that the enema delivery was tolerable and that they would have the treatment again if required. Whilst the study was not designed to measure clinical outcomes, exploratory data also suggested that the active FMT treatment may lead to improvements in gastrointestinal symptoms and quality of life in this population, noting that irritable bowel syndrome is commonly comorbid with MDD.

Conclusions

All feasibility targets were met or exceeded. This study found that enema-delivered FMT is feasible, acceptable, well-tolerated, and safe in patients with MDD. The findings of this study support further research to evaluate clinical efficacy, and the use of this protocol is supported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationMajor Depressive DisorderAdultHumansPilot ProjectsFeasibility StudiesQuality of LifeTreatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

FMTMDDdepressionfaecal microbiota transplantationmajor depressive disordermental disordermental healthmicrobiomemood disorderspsychiatry

Autor:innen und Institutionen

  • Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.
  • Monash Alfred Psychiatry Research Centre (MAPrc), Central Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia.
  • Department of Psychiatry, Peninsula Health, Frankston, Australia.
  • Department of Psychiatry, University of Melbourne, Parkville, Australia.
  • Faculty of Health, Biostatistics Unit, Deakin University, Geelong, Australia.
  • Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Parkville, Australia.

ORCID-Profile: Jessica Emily Green, Michael Berk, David Castle

Förderung

  • Holobiome
  • Wilson Foundation

Zitieren

APA

Green, J. E., Berk, M., Mohebbi, M., Loughman, A., McGuinness, A. J., Castle, D., Chatterton, M. L., Perez, J., Strandwitz, P., Athan, E., Hair, C., Nierenberg, A. A., Cryan, J. F., & Jacka, F. (2023). Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial. The Canadian Journal of Psychiatry, 68(5), 315-326. https://doi.org/10.1177/07067437221150508

Vancouver

Green JE, Berk M, Mohebbi M, Loughman A, McGuinness AJ, Castle D, et al. Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial. The Canadian Journal of Psychiatry. 2023;68(5):315-326. doi:10.1177/07067437221150508

BibTeX
@article{Green2023,
  author = {Green, Jessica Emily and Berk, Michael and Mohebbi, Mohammadreza and Loughman, Amy and McGuinness, Amelia J and Castle, David and Chatterton, Mary Lou and Perez, Joahna and Strandwitz, Philip and Athan, Eugene and Hair, Christopher and Nierenberg, Andrew A and Cryan, John F and Jacka, Felice},
  title = {Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial},
  journal = {The Canadian Journal of Psychiatry},
  year = {2023},
  volume = {68},
  number = {5},
  pages = {315--326},
  doi = {10.1177/07067437221150508}
}
Kostenlos starten →